Cost-effectiveness analysis of filgotinib versus tofacitinib as first-line treatments for rheumatoid arthritis in Greece

Rheumatoid arthritis (RA) is a chronic, progressive disease characterized by joint inflammation and systemic effects. This study evaluates the cost-effectiveness of filgotinib, a selective oral JAK1 inhibitor with a proven efficacy and safety profile, combined with methotrexate for treating patients with moderate to severe active RA who had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) in Greece, compared to tofacitinib.